» Articles » PMID: 38787358

HAMP Predicts a Pivotal Role in Modulating the Malignant Behaviors of Non-small Cell Lung Cancer Cells

Overview
Specialty Geriatrics
Date 2024 May 24
PMID 38787358
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepcidin antimicrobial peptide (HAMP) is a small peptide hormone recognized for its role in iron metabolism and cancer treatment. The purpose of this study was to examine the influence of HAMP in NSCLC.

Methods: The profile of NSCLC cells and tissues was characterized via HAMP. Gain- or loss-of-function cell models of HAMP were constructed, and CCK8, colony formation, and Transwell analyses were used to confirm the influence of HAMP on NSCLC cells. Upstream and downstream HAMP mechanisms in NSCLC were also analysed. Dual-luciferase reporter and pull-down assays confirmed the associations of miR-873-5p with HAMP, miR-873-5p, and the lncRNA KCNQ1OT1/SNHG14/XIST. Moreover, a xenograft model was established in nude mice for confirming the role of HAMP in NSCLC cell growth.

Results: In addition, HAMP expression increased in NSCLC cells and tissues. In terms of cellular functions, the HAMP-overexpressing group exhibited elevated NSCLC cell proliferation, invasion, and migration. HAMP knockdown reversed these changes. Bioinformatics analysis indicated that miR-873-5p targeted HAMP, which affected the nuclear factor kappa B (NF-κB) pathway in NSCLC. HAMP activated the NF-κB pathway, which was negatively modulated by miR-873-5p. NF-κB inhibitor JSH-23 can partly suppress the proliferation, invasion, and migration in HAMP-overexpressed cells. Moreover, miR-873-5p was the target miRNA of long noncoding RNAs (lncRNAs), which included KCNQ1OT1, SNHG14, and XIST, and these three lncRNAs promoted HAMP.

Conclusion: Noncoding RNA-mediated HAMP promotes NSCLC cell proliferation, migration, and invasion by initiating the NF-κB pathway.

Citing Articles

Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer.

Frascatani R, Colella M, Monteleone G Cancers (Basel). 2024; 16(23).

PMID: 39682254 PMC: 11640601. DOI: 10.3390/cancers16234068.

References
1.
Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

2.
Jiao P, Hou J, Yao M, Wu J, Ren G . SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer. Biomed Pharmacother. 2019; 117:109164. DOI: 10.1016/j.biopha.2019.109164. View

3.
Huang J, Liu W, Song S, Li J, Gan K, Shen C . The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma. Front Pharmacol. 2022; 13:1080055. PMC: 9757070. DOI: 10.3389/fphar.2022.1080055. View

4.
Ni S, Yuan Y, Kuang Y, Li X . Iron Metabolism and Immune Regulation. Front Immunol. 2022; 13:816282. PMC: 8983924. DOI: 10.3389/fimmu.2022.816282. View

5.
Wang Y, Jiang X, Qu M, Liang J, Yang J, Sun R . LncRNA KCNQ1OT1/miR-496/HMGB1 Signaling Axis Promotes Invasion and Migration of Non-small Cell Lung Cancer Cells. Biochem Genet. 2023; 62(3):1994-2009. DOI: 10.1007/s10528-023-10526-2. View